Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020

Basit Öğe Kaydı
dc.authorid0000-0003-1513-6149
dc.contributor.authorKılıç, Betül
dc.contributor.authorSerdaroğlu, Esra
dc.contributor.authorGönüllü Polat, Burçin
dc.contributor.authorİnce, Tuğçe
dc.contributor.authorEsenülkü, Gülnur
dc.contributor.authorTopçu, Yasemin
dc.contributor.authorSerdaroğlu, Ayşe
dc.contributor.authorHaspolat, Şenay
dc.contributor.authorTekgül, Hasan
dc.contributor.authorOkuyaz, Çetin
dc.contributor.authorCansu, Ali
dc.contributor.authorAydın, Kürşad
dc.date.accessioned2022-06-03T06:56:22Z
dc.date.available2022-06-03T06:56:22Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose:Valproic acid (VPA) is frequently used and effective in juvenile myoclonic epilepsy (JME). Recently, levetiracetam (LEV) has been suggested as a monotherapy in JME. This study aimed to evaluate antiseizure medication (ASM) use in patients with JME. Methods: Treatment choices in a total of 257 patients (age range 8–18 years, 152 girls, 105 boys) with JME diagnosed and treated between 2010 and 2020 were evaluated retrospectively. Seizure remission was defined as complete seizure control for at least 12 months. Results: Across the study period and entire patient group, VPA was most commonly chosen as the initial ASM (50.9%), followed by LEV (44.4%), and lamotrigine (4.7%). VPA was also the most frequent first choice in the subgroup of boys (73.3%), while LEV was the commonest first choice in girls (57.9%). The sex difference regarding the ASM of the first choice was statistically significant (p<0.001). While VPA was the most frequent initial ASM in the first 5 years of the study period (2010–2015,n = 66, 64%), LEV had taken over as the most popular first ASM in the last 5 years (n = 83, 53.9%, p = 0.005). The most frequent reasons for discontinuation were inefficacy for LEV and adverse effects for VPA (p = 0.001). During follow-up, 237 patients (92.2%) were seizure-free for at least 12 months, and 159 (61.9%) were also in electrographic remission. Seizure remission occurred earlier than electroencephalographic remission (p<0.001). Conclusion: This study revealed that LEV has become the most frequently chosen initial ASM in the treatment of JME. Although LEV appears to have a better adverse effect profile, VPA seems more likely to be effective in achieving seizure control.
dc.identifier.citationKılıç, B., Serdaroğlu, E., Gönüllü Polat, B., İnce, T., Esenülkü, G., Topçu, Y. ... Aydın, K. (2022). Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020. Seizure, 99, 48-53. https://doi.org/10.1016/j.seizure.2022.05.005
dc.identifier.doi10.1016/j.seizure.2022.05.005
dc.identifier.endpage53
dc.identifier.issn1059-1311
dc.identifier.issn1532-2688
dc.identifier.pmid35594744
dc.identifier.scopus2-s2.0-85130314617
dc.identifier.scopusqualityN/A
dc.identifier.startpage48
dc.identifier.urihttps://doi.org/10.1016/j.seizure.2022.05.005
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9490
dc.identifier.volume99
dc.identifier.wos000821623500005en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKılıç, Betül
dc.institutionauthorTopçu, Yasemin
dc.institutionauthorAydın, Kürşad
dc.language.isoen
dc.publisherW.B. Saunders Ltd
dc.relation.ispartofSeizureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectJuvenile Myoclonic Epilepsy
dc.subjectLevetiracetam
dc.subjectValproic Acid
dc.titleTrends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Kilic-Betül-2022.pdf
Boyut:
572.86 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu